Prof. Vincenzo Bronte, M.D. started his research career at the University of Padova (Italy) and then moved to the Surgery Branch of the National Institutes of Health (NIH, Bethesda, USA) in Dr.Restifo’s laboratory, where he was involved in research on cancer  immunology and immunotherapy. During these years, Prof. Bronte was among the first to  define and characterize myeloid cells with immunoregulatory functions, which are now called  myeloid-derived suppressor cells (MDSCs), and whose activity can restrain the efficacy of immunotherapy. Prof. Bronte returned to Italy, initially at the University of Padova/Azienda Ospedaliera as an Independent Researcher, and then at the University of Verona, as a Full Professor in Immunology and Director of the Immunology section of the Medicine Department. In March 2022, he became Scientific Director of the Veneto Institute of Oncology (IOV), the first and only  medical center in the Veneto region specific for the prevention, diagnosis, and treatment of cancer. IOV is a highly specialized health research center of national and international importance, recognized  as a Comprehensive Cancer Center by the Italian Ministry of Health and the Organization of European Cancer Institutes (OECI). During his career, Prof. Bronte contributed to the characterization of the molecular and enzymatic pathways that control and drive myeloid-dependent immunosuppressive activity. He contributed to elucidating MDSC biology in tumor-bearing mice and the ability of these cells to channel the arginine metabolism as an immune regulatory circuit. He participated to clinical studies exploiting MDSC as a potential biomarker of cancer, as well as defining molecular targets to alter their negative effects in tumor-bearing hosts, which has been translated in a few clinical trials. In addition, Prof. Bronte has actively contributed to cancer immunotherapy. In fact, he exploited active immunotherapy strategies based on DNA and viral vaccines, new adjuvants and nanoparticles with immune modulatory properties, as well as passive immunotherapy approaches based on adoptive T cell transfer to tumor-bearing hosts. He is author of 218 articles published in peer-reviewed journals and 17 research monographs, chapters in collective volumes. He was included in the 2023 World Scientist and University Rankings by AD Scientific Index; 2nd edition of Research.com ranking of the best scholars in the field of Immunology, Best Immunology Scientists, 2022; 2021 World’s Top 2% Scientist in the Stanford University Rankings; Highly Cited Researchers from 2018 to 2021 by  “Clarivate Analytics” of researchers with exceptional research performance, multiple highly cited  papers that rank in the top 1% by citations for field and year in Web of Science.